When.com Web Search

  1. Ads

    related to: fda approved treatment resistant depression

Search results

  1. Results From The WOW.Com Content Network
  2. Does Medicare cover ketamine infusions for mental health ...

    www.aol.com/does-medicare-cover-ketamine...

    However, it may cover Spravato, an FDA-approved drug deriving from ketamine, for treatment-resistant depression. Currently, the Food and Drug Administration (FDA) only approves ketamine for use as ...

  3. FDA approves Johnson & Johnson’s ketamine-derived ... - AOL

    www.aol.com/finance/fda-approves-johnson-johnson...

    "Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them,” Bill Martin, neuroscience leader with the ...

  4. Treatment-resistant depression - Wikipedia

    en.wikipedia.org/wiki/Treatment-resistant_depression

    Ketamine has been tested as a rapid-acting antidepressant [13] for treatment-resistant depression in bipolar disorder, and major depressive disorder. [14] Spravato, a nasal spray form of esketamine, was approved by the FDA in 2019 for use in treatment-resistant depression when combined with an oral antidepressant. [15] [16]

  5. Breakthrough antidepressants with fewer side effects could ...

    www.aol.com/finance/breakthrough-antidepressants...

    The FDA approved Johnson & Johnson’s drug for treatment-resistant depression in 2019. Esketamine is derived from a pediatric anesthetic called ketamine. Through research pioneered at Yale ...

  6. Esketamine - Wikipedia

    en.wikipedia.org/wiki/Esketamine

    Esketamine is the second drug to be approved for treatment-resistant depression by the FDA, following olanzapine/fluoxetine (Symbyax) in 2009. [ 26 ] [ 51 ] Other agents, like the atypical antipsychotics aripiprazole (Abilify) and quetiapine (Seroquel), have been approved for use in the adjunctive therapy of major depressive disorder in people ...

  7. Ketamine-assisted psychotherapy - Wikipedia

    en.wikipedia.org/wiki/Ketamine-assisted...

    The US Food and Drug Administration (FDA) first approved the use of intranasal esketamine —an enantiomer of ketamine—for the use of ketamine-derived therapy for treatment-resistant depression, in 2019, [11] leading to the creation and expansion of telemedicine-based companies that practice KAP, such as Mindbloom. [12]

  1. Ad

    related to: fda approved treatment resistant depression